RE: Shares presentation 6th February9 Feb 2024 20:01
Fre1.
Eisai Inc. is a top 100 Japanese Co. Revenues more than $4 bilion. More than 10,000 employees.
I think he said the Eisai pilot study contract that Angle have with them is worth $250,000 (about $5k per patient - 50 patients in the study).
Eisai are in partnership with Bliss Pharma with this trial (both paying for it).
Phase 2 trial (if it goes ahead) approx. $2m to Angle.
Phase 3 trial (if it goes ahead) approx. $5m to Angle.
Eisai have more than 80 cancer trials with more than 60,000 participants (patients).
Seems that Angle could be used more and more when Eisai Inc. do cancer trials. That is my comment.
A distinct possibility I think. Angle's system can give them the information they need before, during and after treatment. Once again a Japanese Co. is on the ball. No mention of big UK pharmas yet. Maybe they are too busy having endless meetings?
I predict a Japanese Co's or USA one will buy Angle Plc in due course.
Angle are such a small Company at the moment frankly they could easily get overwhelmed with orders for their services side. Other Pharma Co's that want Angle's services had better get in fast or it may be a very long wait.
No-one else can offer what Angle can. Simple as that.
All IMHO.